EQS-AFR: SCHOTT Pharma AG & Co. KGaA: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
Werte in diesem Artikel
|
EQS Preliminary announcement financial reports: SCHOTT Pharma AG & Co. KGaA
/ Preliminary announcement on the disclosure of financial statements
Werbung Werbung
SCHOTT Pharma AG & Co. KGaA hereby announces that the following financial reports shall be disclosed:
Report Type: Annual financial report Language: German Date of disclosure: December 11, 2025 Address: http://www.schott-pharma.com/investor-relations/de/news-und-veroeffentlichungen/berichte-und-praesentationen/ Language: English Date of disclosure: December 11, 2025 Address: http://www.schott-pharma.com/investor-relations/news-publications/reports-and-presentations/ Report Type: Annual financial report of the group Language: German Date of disclosure: December 11, 2025 Address: http://www.schott-pharma.com/investor-relations/de/news-und-veroeffentlichungen/berichte-und-praesentationen/ Language: English Date of disclosure: December 11, 2025 Address: http://www.schott-pharma.com/investor-relations/news-publications/reports-and-presentations/
02.04.2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | SCHOTT Pharma AG & Co. KGaA |
| Hattenbergstraße 10 | |
| 55122 Mainz | |
| Germany |
| End of News | EQS News Service |
|
|
2110590 02.04.2025 CET/CEST
Ausgewählte Hebelprodukte auf SCHOTT Pharma
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf SCHOTT Pharma
Der Hebel muss zwischen 2 und 20 liegen
| Name | Hebel | KO | Emittent |
|---|
| Name | Hebel | KO | Emittent |
|---|
Nachrichten zu SCHOTT Pharma
Analysen zu SCHOTT Pharma
| Datum | Rating | Analyst | |
|---|---|---|---|
| 20.05.2025 | SCHOTT Pharma Buy | UBS AG | |
| 20.05.2025 | SCHOTT Pharma Overweight | Barclays Capital | |
| 19.05.2025 | SCHOTT Pharma Hold | Jefferies & Company Inc. | |
| 15.05.2025 | SCHOTT Pharma Buy | UBS AG | |
| 15.05.2025 | SCHOTT Pharma Hold | Jefferies & Company Inc. |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 20.05.2025 | SCHOTT Pharma Buy | UBS AG | |
| 20.05.2025 | SCHOTT Pharma Overweight | Barclays Capital | |
| 15.05.2025 | SCHOTT Pharma Buy | UBS AG | |
| 23.04.2025 | SCHOTT Pharma Buy | UBS AG | |
| 11.04.2025 | SCHOTT Pharma Buy | Deutsche Bank AG |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 19.05.2025 | SCHOTT Pharma Hold | Jefferies & Company Inc. | |
| 15.05.2025 | SCHOTT Pharma Hold | Jefferies & Company Inc. | |
| 11.04.2025 | SCHOTT Pharma Hold | Jefferies & Company Inc. | |
| 25.02.2025 | SCHOTT Pharma Hold | Jefferies & Company Inc. | |
| 17.02.2025 | SCHOTT Pharma Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 13.12.2024 | SCHOTT Pharma Verkaufen | DZ BANK |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für SCHOTT Pharma nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen